Articles about cell therapy

AI2 Incubator spinout Modulus sells cell therapy tech assets to Boston’s Ginkgo Bioworks

The news: Modulus Therapeutics, a Seattle-based cellular therapy company spun out of the Allen Institute of Artificial Intelligence (AI2) Incubator,… Read More

Biotech vet Phil Greenberg on his new cancer-fighting startup and immunotherapy’s next phase

Philip Greenberg has been trying to stop cancer for decades. With Affini-T Therapeutics, the Fred Hutchinson Cancer Research Center investigator… Read More

Bristol Myers Squibb exec on the company’s growth in Seattle and beating cancer with immune cells

Pharmaceutical giant Bristol Myers Squibb has been quietly growing in the Seattle area. Since acquiring Celgene and its Seattle operations… Read More

Cell therapy startup Immusoft lands deal with Takeda worth potentially more than $900M

Seattle-based cell therapy startup Immusoft will collaborate with pharma giant Takeda to develop treatments targeted to the central nervous system… Read More

Seattle biotech vet Justine Dell’Aringa sees parallels in science while building her own home

At home and at work, Justine Dell’Aringa is up for a challenge. The scientific associate director of Translational Research for… Read More

Modulus, a cell therapy biotech incubated at the Allen Institute for AI, raises $3.5M

Modulus Therapeutics, a Seattle-based cellular therapy company spun out of the Allen Institute of Artificial Intelligence (AI2), announced $3.5 million… Read More

Former Juno execs unveil Sana, a new cell engineering biotech that’s reportedly raising more than $800M

Former Juno Therapeutics executives Hans Bishop and Steve Harr have launched Sana Biotechnology, a startup focused on cell therapy, gene… Read More